Literature DB >> 34236718

New-onset cutaneous lichen planus triggered by COVID-19 vaccination.

R Merhy1, A-S Sarkis1, J Kaikati1, L El Khoury2, S Ghosn2, F Stephan1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34236718      PMCID: PMC8447319          DOI: 10.1111/jdv.17504

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   9.228


× No keyword cloud information.

Conflict of interest

Dr. Merhy, Dr Sarkis, Dr. Kaikati, Dr El Khoury, Dr. Ghosn and Dr Stephan, have nothing to disclose.

Funding source

None. To the Editor As the worldwide vaccination campaign against the COVID‐19 pandemic continues, cutaneous manifestations are being increasingly reported as adverse events of the different approved COVID‐19 vaccines for emergency use. , Delayed large local reactions were the most commonly reported cutaneous adverse events, followed by other heterogeneous less common reactions such as urticarial or morbilliform eruptions, pernio/chilblains and pityriasis rosea‐like reactions. Although the cutaneous manifestations triggered by COVID‐19 vaccines are rare, they appear similar to those reported during the pandemic as being related to the infection. , , Reports of lichen planus as a cutaneous manifestation of COVID‐19 vaccination are scarce. Recently, a flare of a pre‐existing lichen planus has been reported following Pfizer vaccine. Herein, we report a case of a new‐onset lichen planus triggered by the Pfizer‐BioNTech COVID‐19 vaccine. A 56‐year‐old woman, with no significant past medical history, presented to our department for a 1‐week history of intense pruritic eruption. The lesions had appeared one week after the first dose of the Pfizer‐BioNTech COVID‐19 vaccine. On the physical examination, erythematous and squamous papules were found predominantly on the trunk, with visible Wickham’s striae on dermoscopy (Fig. 1). No mucosal involvement was noted. A skin biopsy was performed, showing compact hyperkeratosis, hypergranulosis, irregular epidermal hyperplasia and a moderately dense lichenoid lymphocytic infiltrate (Fig. 2a), with the presence of scarce eosinophils in the dermis (Fig. 2b). In view of the clinical picture, the timing of the skin eruption with respect to the vaccine and the histopathologic findings, a drug‐induced lichen planus triggered by the COVID‐19 vaccine has been diagnosed.
Figure 1

Erythematous and squamous papules on the trunk with visible Wickham’s striae.

Figure 2

Photomicrographs showing histopathological changes. (a) (H&E ×100): Microscopy shows compact hyperkeratosis, hypergranulosis, irregular epidermal hyperplasia and a moderately dense lichenoid lymphocytic infiltrate. (b) (H&E ×400): Given the presence of eosinophils (arrow) and parakeratosis a drug‐induced lichen planus is favoured.

Erythematous and squamous papules on the trunk with visible Wickham’s striae. Photomicrographs showing histopathological changes. (a) (H&E ×100): Microscopy shows compact hyperkeratosis, hypergranulosis, irregular epidermal hyperplasia and a moderately dense lichenoid lymphocytic infiltrate. (b) (H&E ×400): Given the presence of eosinophils (arrow) and parakeratosis a drug‐induced lichen planus is favoured. Lichen planus had been frequently associated with different infections, medications and vaccines including HBV vaccination. This is a rare case of new‐onset lichen planus arising after the COVID‐19 vaccination. The vaccination induces a Th1 cell response and a subsequent various cytokines secretion that may play a key role in the development of this condition. The exact pathogenesis is yet to be uncovered. Dermatologists have a crucial role in the diagnosis of cutaneous complications related to COVID‐19 vaccination. Nevertheless, these adverse events and others should not discourage vaccination against a life‐threatening virus.
  7 in total

Review 1.  Lichen planus: a comprehensive evidence-based analysis of medical treatment.

Authors:  H Husein-ElAhmed; U Gieler; M Steinhoff
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-07-22       Impact factor: 6.166

2.  Cutaneous adverse reactions after m-RNA COVID-19 vaccine: early reports from Northeast Italy.

Authors:  E Farinazzo; G Ponis; E Zelin; E Errichetti; G Stinco; C Pinzani; A Gambelli; N De Manzini; L Toffoli; A Moret; M Agozzino; C Conforti; N Di Meo; P Schincariol; I Zalaudek
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-06-07       Impact factor: 9.228

3.  Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: an Italian single centre case series.

Authors:  M Corbeddu; A Diociaiuti; M R Vinci; A Santoro; V Camisa; S Zaffina; M El Hachem
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-04-08       Impact factor: 6.166

4.  Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases.

Authors:  Devon E McMahon; Erin Amerson; Misha Rosenbach; Jules B Lipoff; Danna Moustafa; Anisha Tyagi; Seemal R Desai; Lars E French; Henry W Lim; Bruce H Thiers; George J Hruza; Kimberly G Blumenthal; Lindy P Fox; Esther E Freeman
Journal:  J Am Acad Dermatol       Date:  2021-04-07       Impact factor: 11.527

5.  Lichen planus arising after COVID-19 vaccination.

Authors:  I Hiltun; J Sarriugarte; I Martínez-de-Espronceda; A Garcés; C Llanos; R Vives; J I Yanguas
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-03-28       Impact factor: 6.166

6.  Cutaneous manifestations in SARS-CoV-2 infection (COVID-19): a French experience and a systematic review of the literature.

Authors:  S Matar; B Oulès; P Sohier; O Chosidow; M Beylot-Barry; N Dupin; S Aractingi
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-07-20       Impact factor: 9.228

7.  Pityriasis rosea as a leading manifestation of COVID-19 infection.

Authors:  R Merhy; A S Sarkis; F Stephan
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-12-23       Impact factor: 9.228

  7 in total
  22 in total

1.  Blaschkolinear acquired inflammatory skin eruption (blaschkitis) following COVID-19 vaccination.

Authors:  Roger Rovira-López; Ramon M Pujol
Journal:  JAAD Case Rep       Date:  2022-06-30

2.  COVID vaccine-induced lichen planus on areas previously affected by vitiligo.

Authors:  V Piccolo; C Mazzatenta; A Bassi; G Argenziano; M Cutrone; R Grimalt; T Russo
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-10-02       Impact factor: 9.228

3.  Oral lichen planus following the administration of vector-based COVID-19 vaccine (Ad26.COV2.S).

Authors:  Matthias Troeltzsch; Markus Gogl; Ronald Berndt; Markus Troeltzsch
Journal:  Oral Dis       Date:  2021-09-20       Impact factor: 4.068

4.  Palmoplantar lichenoid drug eruption following the administration of Pfizer-BioNTech COVID-19 vaccine.

Authors:  Giovanni Paolino; Franco Rongioletti
Journal:  JAAD Case Rep       Date:  2022-01-24

5.  Lichen planus flare following COVID-19 vaccination: A case report.

Authors:  Astrid Herzum; Martina Burlando; Mattia F Molle; Claudia Micalizzi; Emanuele Cozzani; Aurora Parodi
Journal:  Clin Case Rep       Date:  2021-12-07

6.  COVID-19 vaccine-related new-onset lichen planus.

Authors:  Arefeh Babazadeh; Ronak Miladi; Mohammad Barary; Maria Shirvani; Soheil Ebrahimpour; Zeinab Aryanian; Zeinab Mohseni Afshar
Journal:  Clin Case Rep       Date:  2022-02-02

7.  A Case of New-Onset Lichen Planus after COVID-19 Vaccination.

Authors:  Vincenzo Picone; Gabriella Fabbrocini; Lorenzo Martora; Fabrizio Martora
Journal:  Dermatol Ther (Heidelb)       Date:  2022-02-15

8.  Cutaneous reactions to COVID-19 vaccines: A review.

Authors:  See Wei Tan; Yew Chong Tam; Shiu Ming Pang
Journal:  JAAD Int       Date:  2022-02-17

9.  Onset of Oral Lichenoid Lesions and Oral Lichen Planus Following COVID-19 Vaccination: A Retrospective Analysis of about 300,000 Vaccinated Patients.

Authors:  Moritz Hertel; Andrea-Maria Schmidt-Westhausen; Stephanie Wendy; Max Heiland; Susanne Nahles; Robert Preissner; Saskia Preissner
Journal:  Vaccines (Basel)       Date:  2022-03-20

10.  Oral erythema multiforme after Pfizer-BioNTech COVID-19 vaccination: a report of four cases.

Authors:  Massimo Petruzzi; Sara Galleggiante; Sabrina Messina; Fedora Della Vella
Journal:  BMC Oral Health       Date:  2022-03-24       Impact factor: 2.757

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.